Contraline Stock
Contraline is developing the first long-lasting, reversible contraceptive for men
About Contraline Stock
Contraline is a biotechnology company developing a long-lasting, non-hormonal, and reversible male contraceptive.
Funding History
| July 2014 | $0 |
|---|---|
| June 2016 | $680K |
| March 2017 | $2.3M |
| July 2018 | $0 |
| September 2018 | $0 |
Management
COO
Nicole E. Hastings
Co-Founder & CEO
Kevin Eisenfrats
Press
The 2018 30 Under 30 In Healthcare
Forbes - Nov, 14 2017
Meet the company that’s looking to make non-surgical male birth control a reality
TechCrunch - Apr, 5 2017
Other Companies
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Contraline or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
